Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA.

Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.

PMID:
29662167
2.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6.

3.

Status of HIV Epidemic Control Among Adolescent Girls and Young Women Aged 15-24 Years - Seven African Countries, 2015-2017.

Brown K, Williams DB, Kinchen S, Saito S, Radin E, Patel H, Low A, Delgado S, Mugurungi O, Musuka G, Tippett Barr BA, Nwankwo-Igomu EA, Ruangtragool L, Hakim AJ, Kalua T, Nyirenda R, Chipungu G, Auld A, Kim E, Payne D, Wadonda-Kabondo N, West C, Brennan E, Deutsch B, Worku A, Jonnalagadda S, Mulenga LB, Dzekedzeke K, Barradas DT, Cai H, Gupta S, Kamocha S, Riggs MA, Sachathep K, Kirungi W, Musinguzi J, Opio A, Biraro S, Bancroft E, Galbraith J, Kiyingi H, Farahani M, Hladik W, Nyangoma E, Ginindza C, Masangane Z, Mhlanga F, Mnisi Z, Munyaradzi P, Zwane A, Burke S, Kayigamba FB, Nuwagaba-Biribonwoha H, Sahabo R, Ao TT, Draghi C, Ryan C, Philip NM, Mosha F, Mulokozi A, Ntigiti P, Ramadhani AA, Somi GR, Makafu C, Mugisha V, Zelothe J, Lavilla K, Lowrance DW, Mdodo R, Gummerson E, Stupp P, Thin K, Frederix K, Davia S, Schwitters AM, McCracken SD, Duong YT, Hoos D, Parekh B, Justman JE, Voetsch AC.

MMWR Morb Mortal Wkly Rep. 2018 Jan 12;67(1):29-32. doi: 10.15585/mmwr.mm6701a6.

4.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: Br J Cancer. 2018 Mar 06;:.

5.

Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer.

Moynihan C, Bancroft EK, Mitra A, Ardern-Jones A, Castro E, Page EC, Eeles RA.

Psychooncology. 2017 Nov;26(11):1987-1993. doi: 10.1002/pon.4530. Epub 2017 Sep 18.

6.

Epidemiology of Invasive Haemophilus influenzae Disease, Europe, 2007-2014.

Whittaker R, Economopoulou A, Dias JG, Bancroft E, Ramliden M, Celentano LP; European Centre for Disease Prevention and Control Country Experts for Invasive Haemophilus influenzae Disease.

Emerg Infect Dis. 2017 Mar;23(3):396-404. doi: 10.3201/eid2303.161552.

7.

Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.

Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J, Benafif S, Dias A, Mikropoulos C, Pope J, Chamberlain A, Gunapala R; SIGNIFY Study Steering Committee, Izatt L, Side L, Walker L, Tomkins S, Cook J, Barwell J, Wiles V, Limb L, Eccles D, Leach MO, Shanley S, Gilbert FJ, Hanson H, Gallagher D, Rajashanker B, Whitehouse RW, Koh DM, Sohaib SA, Evans DG, Eeles RA.

Fam Cancer. 2017 Jul;16(3):433-440. doi: 10.1007/s10689-017-9965-1.

8.

Neurobiological Effects of Morphine after Spinal Cord Injury.

Hook MA, Woller SA, Bancroft E, Aceves M, Funk MK, Hartman J, Garraway SM.

J Neurotrauma. 2017 Feb;34(3):632-644. doi: 10.1089/neu.2016.4507. Epub 2016 Nov 2.

9.

Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury.

Aceves M, Bancroft EA, Aceves AR, Hook MA.

J Neurotrauma. 2017 Mar 15;34(6):1164-1174. doi: 10.1089/neu.2016.4601. Epub 2016 Nov 4.

10.

Mutational signatures of ionizing radiation in second malignancies.

Behjati S, Gundem G, Wedge DC, Roberts ND, Tarpey PS, Cooke SL, Van Loo P, Alexandrov LB, Ramakrishna M, Davies H, Nik-Zainal S, Hardy C, Latimer C, Raine KM, Stebbings L, Menzies A, Jones D, Shepherd R, Butler AP, Teague JW, Jorgensen M, Khatri B, Pillay N, Shlien A, Futreal PA, Badie C; ICGC Prostate Group, McDermott U, Bova GS, Richardson AL, Flanagan AM, Stratton MR, Campbell PJ.

Nat Commun. 2016 Sep 12;7:12605. doi: 10.1038/ncomms12605.

11.

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM Jr, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND.

JAMA Oncol. 2016 Nov 1;2(11):1434-1440. doi: 10.1001/jamaoncol.2016.1820.

12.

The economic and operational value of using drones to transport vaccines.

Haidari LA, Brown ST, Ferguson M, Bancroft E, Spiker M, Wilcox A, Ambikapathi R, Sampath V, Connor DL, Lee BY.

Vaccine. 2016 Jul 25;34(34):4062-7. doi: 10.1016/j.vaccine.2016.06.022. Epub 2016 Jun 20.

13.

The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.

Castro E, Mikropoulos C, Bancroft EK, Dadaev T, Goh C, Taylor N, Saunders E, Borley N, Keating D, Page EC, Saya S, Hazell S, Livni N, deSouza N, Neal D, Hamdy FC, Kumar P, Antoniou AC, Kote-Jarai Z; PROFILE Study Steering Committee, Eeles RA.

Oncologist. 2016 Jun;21(6):716-22. doi: 10.1634/theoncologist.2015-0336. Epub 2016 May 5.

14.

Scale Matters: A Cost-Outcome Analysis of an m-Health Intervention in Malawi.

Larsen-Cooper E, Bancroft E, Rajagopal S, O'Toole M, Levin A.

Telemed J E Health. 2016 Apr;22(4):317-24. doi: 10.1089/tmj.2015.0060. Epub 2015 Sep 8.

15.

Health Care-Associated Infection Outbreak Investigations in Outpatient Settings, Los Angeles County, California, USA, 2000-2012.

OYong K, Coelho L, Bancroft E, Terashita D.

Emerg Infect Dis. 2015 Aug;21(8):1317-21. doi: 10.3201/eid2108.141251.

16.

Infection Prevention and Control in the Podiatric Medical Setting. Challenges to Providing Consistently Safe Care.

Wise ME, Bancroft E, Clement EJ, Hathaway S, High P, Kim M, Lutterloh E, Perz JF, Sehulster LM, Tyson C, White-Comstock MB, Montana B.

J Am Podiatr Med Assoc. 2015 May;105(3):264-72. doi: 10.7547/0003-0538-105.3.264. Review.

PMID:
26146975
17.

Corrigendum to "Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study" [Eur Urol 2014;66:489-99].

Bancroft EK, Eeles RA; authors.

Eur Urol. 2015 Jun;67(6):e126. doi: 10.1016/j.eururo.2014.12.001. Epub 2014 Dec 18. No abstract available.

18.

The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer.

Bancroft EK, Castro E, Bancroft GA, Ardern-Jones A, Moynihan C, Page E, Taylor N, Eeles RA, Rowley E, Cox K.

Psychooncology. 2015 Nov;24(11):1492-9. doi: 10.1002/pon.3814. Epub 2015 Apr 14.

PMID:
25872100
19.

The evolutionary history of lethal metastatic prostate cancer.

Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC; ICGC Prostate Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS.

Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347. Epub 2015 Apr 1.

20.

Infection Prevention and Control in the Podiatric Medical Setting: Challenges to Providing Consistently Safe Care.

Wise ME, Bancroft E, Clement EJ, Hathaway S, High P, Kim M, Lutterloh E, Perz JF, Sehulster LM, Tyson C, White-Comstock MB, Montana B.

J Am Podiatr Med Assoc. 2015 Mar 10. [Epub ahead of print]

PMID:
25756382

Supplemental Content

Loading ...
Support Center